Behrouz Kassaï-Koupai

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
To the Editor: Moscicki and Tandon (Feb. 2 issue)1 present the challenges faced by small biopharmaceutical companies, particularly the small number of patients available for clinical trials involving rare diseases. In our opinion, these challenges are relevant across the whole spectrum of diseases, even the common ones. The “-omics” technologies are leading(More)
  • 1